Weight Loss Medication in Canada: Approved Options, Pills and Cost

Updated September 12, 2026

Canada has six Health Canada-approved medicines for long-term obesity management: Wegovy, Zepbound, Saxenda, Contrave, Xenical and Imcivree. They are not interchangeable, and Imcivree is only for specific rare genetic causes of obesity. Ozempic, Mounjaro and Rybelsus are diabetes brands—not approved weight loss medications in Canada.

The best option depends on your health goals, weight-related conditions, other medications, side-effect risks, preferred form, coverage and ability to continue treatment. Canada’s 2025 adult obesity guideline recommends an individualized assessment, combining medication with health-behaviour support and continuing effective treatment long term.

This guide separates approved obesity medicines from diabetes-only and investigational products, answers which weight loss pills are available, and explains cost, coverage, safety and prescription access in Canada.

Quick Answer: Which Weight Loss Medications Are Approved in Canada?

Health Canada has approved these six medicines for long-term obesity management. The precise age, health and dosing criteria differ by product, so a prescriber must check the current Canadian product monograph for the individual patient.

The authorization list comes from the 2025 Canadian clinical practice guideline update. Authorization does not mean that every product is suitable, available at every pharmacy or covered by every drug plan.

What Is the Best Weight Loss Medication in Canada?

There is no single best medication for everyone. In separate clinical trials, semaglutide and tirzepatide produced larger average weight changes than the older approved medicines, but trial averages are not a head-to-head promise of what one person will experience. Tolerability, health benefits beyond weight, contraindications, cost and long-term access can change the choice.

The 2025 Canadian guideline recommends considering BMI together with waist or other central-adiposity measures and weight-related complications. It also recommends matching treatment to the person’s values, health needs, treatment goals, potential adverse effects, other medications, preferred form and affordability.

• When substantial average weight change is a priority: Wegovy or Zepbound may be discussed if the person meets the indication and has no relevant contraindication.
• When a pill is preferred: Contrave or Xenical may be considered, but they work differently and have different safety limitations.
• When another condition affects the decision: cardiovascular disease, type 2 diabetes, sleep apnea, osteoarthritis and other complications can influence which approved medicine has the most relevant evidence.
• When cost or continuity is the limiting factor: the most effective option on paper may not be practical if it cannot be safely continued.

A prescriber should set health-focused goals and a follow-up plan. Weight-management medication is generally intended as long-term treatment when it is effective and tolerated; stopping can lead to weight regain.

What Weight Loss Pills Are Available in Canada?

For chronic obesity treatment, the main Health Canada-approved oral medicines are Contrave and Xenical.

Contrave

Contrave combines naltrexone and bupropion. It acts on brain pathways involved in appetite and food reward. It may appeal to someone who prefers a tablet, but it is not appropriate with uncontrolled high blood pressure, a seizure disorder, current opioid use or certain other conditions and medicines. The dose is increased according to the product monograph, and the prescriber assesses response and tolerability.

Xenical (orlistat)

Orlistat works in the digestive tract by reducing absorption of some dietary fat. It can cause oily stools, urgency and other gastrointestinal effects, particularly after high-fat meals. It can also affect absorption of fat-soluble vitamins and interact with some medicines. The lower-dose over-the-counter product sold as alli in the United States is not an approved non-prescription weight loss medicine in Canada.

Is Rybelsus a weight loss pill?

Rybelsus is oral semaglutide approved in Canada for type 2 diabetes, not chronic weight management. It should not be presented as an approved obesity pill. Orforglipron, sold as Foundayo in the United States, was still listed by Health Canada as a new drug submission under review for type 2 diabetes as of July 31, 2026; it is not an approved weight loss medication in Canada.

GLP-1 and GIP/GLP-1 Weight Loss Injections

Semaglutide: Wegovy and the new generic option

Semaglutide is a GLP-1 receptor agonist. Wegovy is the brand approved for chronic weight management. On June 29, 2026, Health Canada authorized Sevmia, the first generic semaglutide injection for weight loss. It is a generic version of Wegovy and is indicated for people aged 12 and older as an adjunct to a reduced-calorie diet and increased physical activity.

This is different from generic semaglutide products authorized for type 2 diabetes. Regulatory authorization also does not guarantee that a particular strength is in stock at a pharmacy or that it will be cheaper for every patient. Confirm the prescribed product, dose, availability and price with a pharmacist.

Tirzepatide: Zepbound

Tirzepatide acts at both GIP and GLP-1 receptors. Zepbound is the Canadian brand approved for chronic weight management. The diabetes brand Mounjaro contains the same active ingredient but has a different approved use and should not be treated as interchangeable without a prescriber and pharmacist checking the exact product and indication.

Liraglutide: Saxenda

Saxenda is a daily GLP-1 injection approved for chronic weight management. It may still be considered when clinically appropriate, although the dosing frequency, availability, tolerability and coverage may make another option more practical.

For a broader explanation of this medication class, see our GLP-1 medications in Canada guide.

Approved Obesity Medicines vs Diabetes Brands

The brand name and approved purpose matter. These diabetes medicines are not Health Canada-approved weight loss drugs:

• Ozempic: injectable semaglutide approved for type 2 diabetes.
• Rybelsus: oral semaglutide approved for type 2 diabetes.
• Mounjaro: tirzepatide approved for type 2 diabetes.

The 2025 Canadian adult obesity guideline recommends against compounded products and prescription or over-the-counter medicines that are not approved in Canada for weight loss. A person who also has diabetes may have a separate reason to discuss a diabetes medicine with their clinician, but weight-management advertising and online offers should not blur those indications.

Phentermine and diethylpropion products formerly sold in Canada are discontinued. Qsymia is not approved by Health Canada. Products promoted online as “natural Ozempic,” research peptides or non-prescription GLP-1 substitutes are not equivalent to an authorized prescription medicine.

Who May Be Eligible for Weight Loss Medication?

In adults, the 2025 Canadian guideline recommends offering approved obesity pharmacotherapy, together with health-behaviour changes, at a BMI of 30 or higher, or a BMI of 27 or higher with weight-related complications. It also advises using waist or other central-adiposity measures, ethnicity-appropriate thresholds and the person’s complications rather than relying on BMI alone.

A medical assessment may include:

• weight history, goals and the effect of weight on health and daily life;
• BMI, waist measures and conditions such as high blood pressure, sleep apnea, diabetes, cardiovascular disease or osteoarthritis;
• current medicines, allergies, pregnancy plans and relevant personal or family history;
• eating patterns, activity, sleep, mental health and possible contributors to weight change;
• baseline examination or laboratory testing when clinically indicated; and
• a plan for dose adjustment, side-effect monitoring, response and longer-term follow-up.

Meeting a BMI threshold does not guarantee a prescription. The clinician must decide whether a specific medicine is indicated and safe, and some concerns may need an in-person assessment or care elsewhere.

How to Get Weight Loss Medication in Canada

Approved obesity medicines are prescription drugs. A legitimate Canadian route involves an assessment by a licensed prescriber and dispensing by a licensed pharmacy. Avoid sellers that offer prescription GLP-1 products without an assessment, hide the source or ingredient, or label an unapproved peptide as “research use.” Health Canada advises Canadians to buy GLP-1 medicines only from licensed pharmacies.

A phone or video visit may be appropriate for part of the assessment when the clinician has enough information to provide safe care. Telehealth does not guarantee a prescription and is not a substitute for any examination, test or follow-up the clinician considers necessary.

Weight Loss Medication Cost and Coverage in Canada

There is no reliable single Canadian price. What a patient pays depends on the exact product and dose, pharmacy fees and markups, province or territory, public-plan criteria, private insurance and manufacturer or pharmacy programs. Authorization by Health Canada does not automatically mean public or private coverage.

Before starting, ask:

• Does the plan cover this exact drug identification number and indication?
• Is prior or special authorization required, and who submits it?
• Is there a deductible, annual maximum, step requirement or percentage co-pay?
• What is the pharmacy’s current cash price for the prescribed dose?
• Will the cost change as the dose changes?
• Is the medicine currently available, and is a different authorized product actually interchangeable?

In British Columbia, patients and prescribers can check the current PharmaCare drug-coverage information and any Special Authority criteria. Private plans vary, so contact the insurer using the exact product name and DIN. A medical appointment being publicly insured does not mean the prescribed medicine is covered.

Generic semaglutide may improve price competition, but “generic Ozempic” and “generic Wegovy” refer to different approved uses. Do not assume a diabetes generic is an approved or covered substitute for obesity treatment.

Side Effects and Safety

All weight loss medicines can cause side effects, and “approved” does not mean risk-free. Read the pharmacy label and product monograph, and tell the prescriber about all prescription, non-prescription and natural health products.

GLP-1 and GIP/GLP-1 medicines

Nausea, vomiting, diarrhea, constipation and abdominal discomfort are common, especially while the dose is being increased. Product-specific concerns can include gallbladder problems, pancreatitis, dehydration and kidney problems, low blood sugar when combined with certain diabetes medicines, and delayed stomach emptying that can affect procedures or other medicines. These products are generally not used during pregnancy, and some have specific thyroid-tumour contraindications. Do not combine GLP-1 medicines unless a prescriber specifically directs it.

Contrave

Common effects include nausea, constipation, headache, dizziness, dry mouth and insomnia. Contrave is not appropriate for some people with uncontrolled hypertension, seizure risk, eating disorders, abrupt withdrawal from alcohol or sedatives, opioid use, pregnancy or certain medicine interactions. Naltrexone can block opioid pain medicines and may precipitate withdrawal.

Xenical

Oily stools, urgency, gas and more frequent bowel movements are common. Orlistat can reduce absorption of fat-soluble vitamins and interact with medicines including some anticoagulants, thyroid medicine, seizure medicines and transplant medicines. A prescriber or pharmacist can advise on spacing and supplementation.

Seek urgent medical advice for severe or persistent abdominal pain, repeated vomiting with inability to keep fluids down, signs of a serious allergic reaction or other severe symptoms. For non-urgent side effects, contact the prescriber or pharmacist before changing or stopping treatment.

What New Weight Loss Drugs Are Coming to Canada?

Retatrutide remains investigational and is not approved by Health Canada. Orforglipron is approved in the United States as Foundayo, but not in Canada; Health Canada’s new-drug-submission list dated July 31, 2026 showed orforglipron under review for type 2 diabetes. Canadian authorization, indication, timing, availability, price and coverage should not be assumed before a final regulatory decision.

Frequently Asked Questions

What is the strongest weight loss pill in Canada?

“Strongest” is not the same as safest or most suitable. Contrave and Xenical are the main approved oral options for chronic obesity treatment, and they have not produced the same average trial weight changes as the leading injections. The choice depends on contraindications, goals, side effects, interactions and affordability. Rybelsus is not approved as a weight loss pill in Canada.

Can I buy weight loss medication over the counter in Canada?

Canada does not have an approved over-the-counter equivalent of Wegovy, Zepbound, Contrave or Xenical for chronic obesity treatment. Supplements, compounded products and products sold as “natural Ozempic” are not approved substitutes. Prescription medicines should come from a licensed pharmacy after an appropriate assessment.

Does insurance cover weight loss medication in Canada?

Sometimes. Coverage depends on the exact drug, indication, province or territory, insurer and plan. Some plans exclude obesity medicines, while others require prior authorization or proof that clinical criteria are met. Check the exact DIN and current plan rules rather than relying on a general drug name.

Can I get a weight loss prescription online?

An online assessment may be appropriate when a licensed clinician can assess the issue safely. A prescription is never guaranteed. The clinician may request measurements, records, tests, follow-up or an in-person assessment before deciding whether medication is appropriate.

Can Ozempic or Mounjaro be used for weight loss?

Ozempic and Mounjaro are approved in Canada for type 2 diabetes, not obesity. Wegovy and Zepbound are the corresponding obesity-approved brands. Canada’s 2025 obesity guideline recommends using medicines approved for weight management rather than non-approved or compounded products.

Is there a safest weight loss medication?

No product is safest for everyone. A lower average weight effect does not automatically mean lower risk, and a highly effective medicine may be unsuitable because of a contraindication, interaction or access problem. Safety comes from choosing the right product for the individual, obtaining it from a licensed pharmacy and monitoring it properly.

Discuss Weight Loss Treatment With a Physician

Weight loss medication can be one part of long-term, evidence-based obesity care. The most useful next step is a medical assessment that separates approved options from marketing claims and considers health benefits, risks, preferences, cost and follow-up.

Walk In connects eligible patients in selected Metro Vancouver communities with BC-licensed physicians for phone or video appointments when available. A physician can assess whether weight-management treatment is appropriate; a prescription depends on the clinical assessment, and some concerns may require in-person care or another service.

Speak With a Doctor About Weight Loss Treatment